That is why it is called a triple agonist. In an 80-week phase 3 trial published in November 2026, adults with obesity lost 25.0% of their weight on the 12 mg dose, against 3.9% on placebo.1 We found no Eli Lilly label for it on DailyMed, the U.S. database of drug labels, on November 20, 2026.2
What it is
Tirzepatide, the molecule in Mounjaro and Zepbound, activates two receptors, GIP and GLP-1. Retatrutide adds a third, the receptor for glucagon, a hormone from the pancreas.1,3 In the trials it was given once a week under the skin. The phase 2 trial started some groups at 2 mg and others at 4 mg before raising the dose, and tested final doses from 1 mg to 12 mg.3
The phase 2 trial
The first large report, in 2023, enrolled 338 adults with obesity, or with overweight and a weight-related condition, for 48 weeks. Weight fell by 8.7% on 1 mg, 17.1% on 4 mg, 22.8% on 8 mg and 24.2% on 12 mg, against 2.1% on placebo.3 On 12 mg, 83% lost at least 15% of their weight, against 2% on placebo.3
The side effects followed a familiar pattern. The most common were in the stomach and gut; they rose with the dose, were mostly mild to moderate, and were partly eased by starting at 2 mg rather than 4 mg. Heart rate rose with the dose, peaked at 24 weeks and declined afterwards.3 A lower start easing side effects is the same logic as the slow dose climb of the approved medicines.
TRIUMPH-1, the phase 3 trial
TRIUMPH-1 enrolled 2,339 adults with obesity and without diabetes and gave them retatrutide 4 mg, 9 mg or 12 mg, or placebo, once a week for 80 weeks. Weight fell by 17.6%, 23.7% and 25.0% on the three doses, against 3.9% on placebo.1
The trial also measured two conditions linked to weight:1
- Knee osteoarthritis. In 574 participants with it, knee pain on a 10-point scale fell by 3.5 and 3.6 points on 9 mg and 12 mg, against 1.9 on placebo.
- Obstructive sleep apnea. In 243 participants with it, the apnea-hypopnea index fell by 34.3 and 31.7 events an hour on 9 mg and 12 mg, against 9.9 on placebo.
The authors report that the most common adverse events were in the stomach and gut. The trial was funded by Eli Lilly.1
Next to the approved medicines
The numbers are larger than in the label trials of the approved weight medicines: 20.9% on Zepbound 15 mg over 72 weeks and 14.9% on Wegovy 2.4 mg over 68 weeks.4,5 Those trials ran at different times, for different lengths and in different people, so the gap is a rough guide only. No trial has put retatrutide against tirzepatide or semaglutide directly in the sources we read. What the trials do show is a dose effect: in both, each step up from 4 mg to 12 mg brought more weight loss, with the largest jump between 4 mg and the middle dose.1,3
Retatrutide sold online
Because it is in the news, retatrutide is offered online. DailyMed lists 10 product labels for retatrutide pens and powders, several under the name Salkalli, all from one company, Guangzhou Yixin Cross-border E-commerce, with the marketing status "Export only" and the listing dated November 2025.2 A listing on DailyMed is not an FDA approval, and these products have no application number on their pages. The FDA's warnings about unapproved GLP-1 products, set out on our page on compounded semaglutide, apply to anything sold this way.6
Sources
- Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med 2026;395:1781-1793. Funded by Eli Lilly. doi:10.1056/NEJMoa2604169
- DailyMed, U.S. National Library of Medicine. Search for "retatrutide", 10 results, all from Guangzhou Yixin Cross-border E-commerce Co., Ltd., marketing status "Export only"; read November 20, 2026. dailymed.nlm.nih.gov
- Jastreboff AM, Kaplan LM, Fr铆as JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389:514-526. doi:10.1056/NEJMoa2301972
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
Related analyses
Ozempic vs Zepbound: two drugs, two labels, and the trials that compared them
Compounded semaglutide and tirzepatide in 2026: what FDA allows, what it has reported, and what to check
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Zepbound plateau: when weight loss slows, why, and what the trials show
Log any GLP-1 medicine you take and see your doses, weight and symptoms together.
Open Dose Insider